时间：2021-02-03 14:07:50人气：4673来源： 欧中之声
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Guangdong hosts Chinese New Year Eve's Feast for global friends to celebrate reunion
(13235)人喜欢2025-01-21
What makes Shunde a must-visit for hidden gems and authentic flavors?
(14344)人喜欢2025-01-21
Whyte on Two Sessions | The CPPCC system allows more people to participate in social development
(15446)人喜欢2025-01-21
Recap | What to learn from Guangdong
(8776)人喜欢2025-01-21
Didi at the Hall | Guangdong’s economy shows resilience amid global economic challenges, say consuls general in Guangzhou
(14351)人喜欢2025-01-17
China Xplained | Take a look at highlights of 2025 Guangdong Government Work Report
(14347)人喜欢2025-01-17
YMCG Orchestra enchants GBA with melodies
(13259)人喜欢2025-01-17
Railway station greets passengers with CNY events as Chunyun begins
(18789)人喜欢2025-01-15